QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
MWN-AI** Summary
Hagens Berman, a national shareholder rights law firm, has intensified its investigation into uniQure N.V. (NASDAQ: QURE) following significant rebukes from the Food and Drug Administration (FDA). This investigation is part of a securities class action lawsuit aimed at representing investors who bought uniQure ordinary shares between September 24, 2025, and October 31, 2025. The firm has set an April 13, 2026, deadline for investors to act as Lead Plaintiffs in the lawsuit.
Key allegations stem from a public call where an FDA official criticized uniQure's lead gene therapy candidate, AMT-130, labeling it a “failed therapy.” The official accused the company of presenting “distorted” data, particularly regarding its trial design and requirements. A notable point of contention was the accusation of mischaracterizing sham surgeries needed for the study. Contrary to uniQure’s claims, the FDA clarified that only minimal incisions, not invasive skull drilling, were mandated.
Further disputes arose concerning uniQure’s assertion that it had previous FDA agreement on trial conditions, which the FDA official refuted. Investors were reportedly misled regarding the clinical study's basis and the timelines for a Biologics License Application (BLA), particularly after a November 2025 revelation led to a significant stock drop of 49%.
The ongoing class action, Scocco v. uniQure N.V., alleges that uniQure consistently failed to disclose crucial information regarding regulatory approval, downplayed essential surgery requirements, and misled investors on anticipated timelines. Investors who incurred losses during the specified period are encouraged to take action before the approaching deadline and can seek further information on the Hagens Berman QURE Case Page.
MWN-AI** Analysis
The recent developments surrounding uniQure N.V. (NASDAQ: QURE) serve as a stark reminder of the volatile nature of biotech investments, especially when regulatory scrutiny becomes intense. Following a series of critical remarks from the FDA regarding the company’s lead gene therapy candidate, AMT-130, shareholders must tread carefully.
The FDA has publicly challenged uniQure's claims, labeling its data comparisons as "distorted" and indicating possible miscommunication about the nature of necessary clinical trials. These revelations have prompted a securities class action, raising significant concerns about the transparency of uniQure's regulatory interactions. The details surrounding the need for sham surgeries and the FDA's rejection of a previously suggested comparison method add layers of complexity to the company's regulatory strategy, suggesting potential misrepresentations that could have legal repercussions.
Given the allegations against uniQure and the resultant volatility in its stock, investors should closely monitor the unfolding legal situation and regulatory guidance. Those who purchased shares during the alleged "Class Period" have until April 13, 2026, to potentially join the class action lawsuit, emphasizing the urgency for shareholders to assess their positions.
In light of this turmoil, potential investors may want to adopt a cautious approach. Holding existing shares could expose investors to further losses, particularly if the FDA continues to reject uniQure’s methodologies. Conversely, opportunities may arise for speculative investors looking to capitalize on dips in share prices.
Investors should utilize this situation to reassess their risk tolerance and investment strategies, particularly in biotech stocks where the stakes are high and regulatory decisions can profoundly impact share values. Monitoring updates from the FDA and litigation outcomes will be crucial in determining the future trajectory of uniQure’s stock.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit
SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.
SUBMIT YOUR QURE LOSSES TO HBSS NOW
The FDA Clash: "A Distorted or Manipulated Comparison"
On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.
The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the mind of FDA" instead of running a correct clinical study.
Key revelations from the March 6 disclosure include:
- Sham Surgery Mischaracterization: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, accusing the company of mischaracterizing the agency's request. The official clarified that the FDA did not ask to "drill holes in skulls," but rather required "one to three nicks in the scalp" under minimal anesthesia.
- Denial of Prior Agreement: While uniQure CEO Matt Kapusta described the sham surgery requirement as a "drastic change" from previous guidance, the FDA official pushed back, stating the agency "never agreed to accept this distorted comparison" using natural history as a comparator.
- Ineligibility for "Plausible Mechanism" Pathway: The official disputed AMT-130's eligibility for streamlined rare-disease pathways, noting it is not an individualized treatment.
The recent reports follow the filing of a securities class action suit.
Investors in uniQure (QURE) are encouraged to visit the Hagens Berman QURE Case Page to review the allegations in the pending litigation: www.hbsslaw.com/cases/uniqure
"The pending securities class action alleges a consistent pattern: that uniQure misrepresented its interactions with the FDA and used a pivotal study design that it knew the agency had not approved," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claim in the pending litigation.
Summary of QURE Class Action Allegations: The "Pivotal" Study Mirage
The securities class action, Scocco v. uniQure N.V., et al. (S.D.N.Y.), alleges that throughout the Class Period (Sept. 24, 2025 – Oct. 31, 2025), defendants failed to disclose:
- No Regulatory Consensus: That the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130.
- Hidden Requirements: That uniQure downplayed the necessity of a sham-controlled surgery arm for Phase III—a requirement the FDA now claims was never waived.
- Timeline Deception: That defendants misled investors regarding the timing of a Biologics License Application (BLA), which was rendered "unclear" once the lack of FDA agreement was revealed on November 3, 2025, sending the stock down 49%.
Critical Deadline: April 21, 2026
If you purchased uniQure ordinary shares during the Class Period (Sept. 24, 2025 – Oct. 31, 2025) and suffered losses, you have until April 13, 2026, to ask the Court to appoint you as Lead Plaintiff.
- Submit Your QURE Losses to HBSS Now
- Contact: Reed Kathrein at 844-916-0895 or email QURE@hbsslaw.com
If you'd like more information and answers to additional frequently asked questions about the uniQure case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding uniQure should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email QURE@hbslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SOURCE Hagens Berman Sobol Shapiro LLP
FAQ**
What are the specific allegations against uniQure N.V. QURE regarding their interactions with the FDA, and how do these allegations impact the company's credibility in the eyes of investors?
How has the FDA's characterization of AMT-130 as a "failed therapy" influenced investor sentiment and the stock price of uniQure N.V. QURE since the public statements were made?
What are the potential legal implications for uniQure N.V. QURE if the allegations of misrepresentation in the securities class action lawsuit prove to be true?
How might the required sham-controlled surgery arm for Phase III studies affect the future development and commercialization plans of uniQure N.V. QURE's gene therapy candidates?
**MWN-AI FAQ is based on asking OpenAI questions about uniQure N.V. (NASDAQ: QURE).
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
